Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Authors:
Open Access
- 10 August 2019
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 62 (10) , 1854-1867
Abstract
Aims/hypothesis An increased risk of fracture with canagliflozin vs placebo was reported from the CANagliflozin cardioVascular Assessment Study (CANVAS) Program, with heterogeneity of findings identified between the two trials that comprise the CANVAS Program, CANVAS and CANVAS-R. The objective of these analyses was to identify reasons for the possibly different effects on fracture observed between CANVAS and CANVAS-R. Methods This study was an analysis of two highly similar trials, CANVAS and CANVAS-R, conducted in 10,142 individuals with type 2 diabetes and history or high risk of cardiovascular disease who received canagliflozin (pooled 100/300 mg once daily) or placebo. Outcomes assessed in this analysis were effects on adjudicated fractures overall and by type, location, association with a fall, dose and follow-up time. Results A total of 496 participants recorded ≥1 fracture event during follow-up (15.40 vs 11.93 per 1000 patient-years with canagliflozin vs placebo; HR 1.26 [95% CI 1.04, 1.52]). There was significant heterogeneity in the effects on fracture (p = 0.005) between CANVAS (n = 4330: HR 1.55 [95% CI 1.21, 1.97]) and CANVAS-R (n = 5812: HR 0.86 [95% CI 0.62, 1.19]). The between-study heterogeneity in fracture risk was not clearly explained by differences in baseline characteristics, interactions of randomised treatment with participant characteristics, dose effects, duration of follow-up, metabolic effects, adverse events related to falls or adverse events possibly causing falls. Conclusions/interpretation There was no evidence to explain clearly the fracture risk observed in the CANVAS Program or the heterogeneity in fracture risk between the two studies. The recently reported null result for fracture in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial suggests that the observed association in CANVAS is likely to be a chance finding, although an unidentified fall-related mechanism remains a possibility. Trial registration: ClinicalTrials.gov NCT01032629, NCT01989754.Keywords
Funding Information
- Janssen Research & Development, LLC
This publication has 25 references indexed in Scilit:
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With CanagliflozinThe Journal of Clinical Endocrinology & Metabolism, 2016
- Effects of diabetes drugs on the skeletonBone, 2016
- Increased fracture risk in patients with type 2 diabetes mellitus: An overview of the underlying mechanisms and the usefulness of imaging modalities and fracture risk assessment toolsMaturitas, 2014
- Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trialsBone, 2014
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)Current Medical Research and Opinion, 2014
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trialAmerican Heart Journal, 2013
- Type 2 diabetes and boneJournal of Bone and Mineral Research, 2012
- Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studiesEuropean Journal of Epidemiology, 2012
- The Role of Falls in Fracture PredictionCurrent Osteoporosis Reports, 2011
- Rosiglitazone-Associated Fractures in Type 2 DiabetesDiabetes Care, 2008